Accessibility Menu
Heron Therapeutics Stock Quote

Heron Therapeutics (NASDAQ: HRTX)

$1.30
(-3.7%)
-0.05
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$1.3
Daily Change
(-3.7%) $0.05
Day's Range
$1.29 - $1.36
Previous Close
$1.3
Open
$1.35
Beta
1.56
Volume
1,957,298
Average Volume
1,699,371
Market Cap
247.5M
Market Cap / Employee
$1.35M
52wk Range
$1.04 - $2.68
Revenue
-
Gross Margin
0.75%
Dividend Yield
N/A
EPS
-$0.01
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Heron Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
HRTX-28.18%-92.09%-39.8%-100%
S&P+15.06%+95.03%+14.29%+1,913%

Heron Therapeutics Company Info

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$37.20M3.3%
Gross Profit$27.34M7.2%
Gross Margin73.50%2.7%
Market Cap$315.81M-40.1%
Market Cap / Employee$2.59M0.0%
Employees122-3.2%
Net Income-$2.38M74.2%
EBITDA-$0.83M85.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$16.52M-10.2%
Accounts Receivable$79.93M8.4%
Inventory7370.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M-100.0%
Short Term Debt$176.74M5433.6%

Ratios

Q2 2025YOY Change
Return On Assets-0.41%22.5%
Return On Invested Capital-75.97%7.9%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$11.08M-111.3%
Operating Free Cash Flow-$10.87M-136.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-7.55-5.80-9.95-11.09-28.86%
Price to Sales2.211.622.922.13-45.52%
Price to Tangible Book Value-7.55-5.80-9.95-11.09-28.86%
Enterprise Value to EBITDA-106.1474.21151.09-550.76396.04%
Total Debt$178.25M$177.76M$177.26M$176.74M-1.10%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.